MX378112B - Anticuerpos que potencian el factor h y sus usos. - Google Patents

Anticuerpos que potencian el factor h y sus usos.

Info

Publication number
MX378112B
MX378112B MX2017002277A MX2017002277A MX378112B MX 378112 B MX378112 B MX 378112B MX 2017002277 A MX2017002277 A MX 2017002277A MX 2017002277 A MX2017002277 A MX 2017002277A MX 378112 B MX378112 B MX 378112B
Authority
MX
Mexico
Prior art keywords
antibodies
boost factor
fragments
factor
complement activation
Prior art date
Application number
MX2017002277A
Other languages
English (en)
Other versions
MX2017002277A (es
Inventor
Diana Wouters
Maria Clara Brouwer
Richard Benjamin Pouw
Taco Willem Kuijpers
Original Assignee
Stichting Sanquin Bloedvoorziening
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Sanquin Bloedvoorziening filed Critical Stichting Sanquin Bloedvoorziening
Publication of MX2017002277A publication Critical patent/MX2017002277A/es
Publication of MX378112B publication Critical patent/MX378112B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos aislados, sintéticos o recombinantes y fragmentos de ellos específicos para el factor H. La invención se refiere además al uso de dichos anticuerpos y fragmentos para inhibir la activación del complemento y para el tratamiento de trastornos asociados con la activación del complemento.
MX2017002277A 2014-08-20 2015-08-20 Anticuerpos que potencian el factor h y sus usos. MX378112B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14181631 2014-08-20
PCT/NL2015/050584 WO2016028150A1 (en) 2014-08-20 2015-08-20 Factor h potentiating antibodies and uses thereof

Publications (2)

Publication Number Publication Date
MX2017002277A MX2017002277A (es) 2017-08-10
MX378112B true MX378112B (es) 2025-03-10

Family

ID=51357866

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002277A MX378112B (es) 2014-08-20 2015-08-20 Anticuerpos que potencian el factor h y sus usos.

Country Status (12)

Country Link
US (2) US10112993B2 (es)
EP (1) EP3183266B1 (es)
JP (2) JP6965157B2 (es)
KR (1) KR102709811B1 (es)
CN (1) CN107074939B (es)
AU (1) AU2015304079B2 (es)
BR (2) BR112017003200B1 (es)
CA (1) CA2958537C (es)
ES (1) ES2739609T3 (es)
IL (1) IL250667B2 (es)
MX (1) MX378112B (es)
WO (1) WO2016028150A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020014399A2 (pt) * 2018-01-15 2020-12-29 Stichting Sanquin Bloedvoorziening Anticorpos potenciadores do fator h e seus usos
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
BR112022000739A2 (pt) * 2019-07-17 2022-04-12 Gemini Therapeutics Sub Inc Anticorpos de potencialização de fator h e usos dos mesmos

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006012621A2 (en) * 2004-07-23 2006-02-02 University Of Virginia Patent Foundation Compositions and methods for regulating the alternative pathway of complement
HUE026423T2 (en) * 2005-11-04 2016-05-30 Genentech Inc Use of complement biosynthetic pathway inhibitors for treating eye diseases
FR2894145B1 (fr) * 2005-12-07 2008-10-17 Lab Francais Du Fractionnement Utilisation de facteur h du complement a titre de medicament
KR20150029002A (ko) * 2007-06-07 2015-03-17 제넨테크, 인크. 보체-관련 장애의 예방 및 치료를 위한 Ｃ３ｂ 항체 및 방법
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition
JP6092776B2 (ja) * 2010-09-15 2017-03-08 セルデックス セラピューティクス インコーポレイテッド 可溶性補体受容体Ｉ型（ｓＣＲ１）を用いる慢性腎症の処置
CN104870474B (zh) * 2012-10-04 2019-03-12 诺沃姆德治疗公司 用于治疗溶血性疾病的旁路途径特异性抗体
WO2015067755A2 (en) * 2013-11-07 2015-05-14 Novo Nordisk A/S Novel methods and antibodies for treating coagulapathy
WO2015070207A2 (en) * 2013-11-11 2015-05-14 The Government Of The United States, As Represented By The Secretary Of The Army Ama-1 epitopes, antibodies, compositions, and methods of making and using the same

Also Published As

Publication number Publication date
IL250667B1 (en) 2023-06-01
JP2021178857A (ja) 2021-11-18
US10112993B2 (en) 2018-10-30
JP2017525362A (ja) 2017-09-07
ES2739609T3 (es) 2020-02-03
AU2015304079A1 (en) 2017-04-06
US20170355753A1 (en) 2017-12-14
CN107074939B (zh) 2021-09-07
IL250667B2 (en) 2023-10-01
EP3183266B1 (en) 2019-05-29
MX2017002277A (es) 2017-08-10
WO2016028150A1 (en) 2016-02-25
BR112017003200B1 (pt) 2023-12-26
KR20170058922A (ko) 2017-05-29
BR122023020102A2 (pt) 2023-12-12
CA2958537A1 (en) 2016-02-25
KR102709811B1 (ko) 2024-09-24
IL250667A0 (en) 2017-04-30
CA2958537C (en) 2023-04-25
CN107074939A (zh) 2017-08-18
AU2015304079B2 (en) 2021-05-13
JP6965157B2 (ja) 2021-11-10
US20190194304A1 (en) 2019-06-27
BR112017003200A2 (pt) 2017-11-28
EP3183266A1 (en) 2017-06-28

Similar Documents

Publication Publication Date Title
CL2018001384A1 (es) Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales
CO2017003487A2 (es) Composiciones que comprenden polipéptidos gdf15 modificados para trastornos metabólicos
ZA201902141B (en) Acid-alpha glucosidase variants and uses thereof
MY193723A (en) Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
MX2016012880A (es) Cadena j modificada.
PH12017500877B1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
MX2018005613A (es) Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos.
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
ZA201902140B (en) Acid-alpha glucosidase variants and uses thereof
MX2016012371A (es) Anticuerpos multiespecificos.
MY176855A (en) Anti-jagged1 antibodies and methods of use
ECSP17003946A (es) Anticuerpos antagonistas del interferón alfa y omega
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
CO2018008249A2 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b
CL2017000087A1 (es) Un proceso novedoso para la purificación de rhu-gcsf
MX386150B (es) Tasimelteon para tratar el síndrome de smith-magenis.
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MX378112B (es) Anticuerpos que potencian el factor h y sus usos.
EA201791813A1 (ru) Применение выделенных фракций мастиковой смолы для лечения нейропатии зрительного нерва
PH12017500499A1 (en) Synthesis of ent-progesterone and intermediates thereof
MX383460B (es) Derivados peptidicos novedosos y sus usos.
MX368972B (es) Composiciones de glicoproteínas sialiladas y usos de estas.
MX2016010967A (es) Nuevas composiciones para tratar lesiones neuronales mecanicas.
MX376367B (es) Activacion del factor x.